We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. In 2024, Healio covered several stories about trials ...

A novel measure of geographic atrophy shows a stronger correlation with vision loss than the area of the lesion and could aid ...

Editor's note: This is an automatically generated transcript. Please notify [email protected] if there are concerns regarding accuracy of the transcription. The treatment landscape in geographic ...

Management of geographic atrophy (GA) has changed with the introduction of retinal therapies aimed at slowing disease ...

PulseSight Therapeutics SAS, an ophthalmology clinical stage biotech company developing disruptive vectorized gene therapies with minimally-invasive delivery technology, is pleased to announce the ...

Ocugen, Inc. has completed enrollment in the Phase 2 portion of its clinical trial for OCU410, a novel gene therapy aimed at treating geographic atrophy (GA) associated with dry age-related macular ...

Geographic atrophy (GA) progressed more often in patients with better baseline vision and those with lesions closer to the foveal center, according to a study that could help provide needed treatment ...

Apellis Pharmaceuticals, Inc. announced that the Therapeutic Goods Administration (TGA) in Australia has approved its treatment SYFOVRE® (pegcetacoplan) for adult patients suffering from geographic ...

—Certain imaging biomarkers and demographic factors are associated with geographic atrophy growth rate and may guide the selection of patients for the use of newer therapeutics. As the population ...

Ocugen also reported updated results from a phase 1 trial, which showed that ellipsoid zone (EZ) loss – which results in the ...

Phase 2 (~50% of patients evaluated to date at 12 months) shows 46% lesion growth reduction vs. controlThere are no OCU410-related serious adverse events reported across the Phase 1 and Phase 2 ...